Reduced PD-L1 positivity was linked to higher IDH1 (R132H) expression, indicating that IDH1 (R132H) mutations may alter immune checkpoint pathways and affect tumor immune evasion strategies (Figure 10). Here, IDH1 is linked to neoplasm.